Bladder Cancer in Iran: An Epidemiological Review.
Iran
bladder cancer
epidemiology
incidence
risk factor
Journal
Research and reports in urology
ISSN: 2253-2447
Titre abrégé: Res Rep Urol
Pays: England
ID NLM: 101576971
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
09
2019
accepted:
06
01
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Bladder cancer is the sixth most common cancer in Iran. Information about the epidemiological situation of the disease and its risk factors is necessary for conducting a planning program to reduce the disease. This study is conducted with the aim of evaluating the epidemiological features of bladder cancer in Iran. This is a systematic review of the published articles in both Persian and English in international and national journals during the years 2000-2019 with key words of Iran and bladder cancer. Articles were selected from the national information database (SID, Magiran) and international databases (PubMed, Scopus, and Web of Science). Articles related to the epidemiological aspects of the disease, including incidence, prevalence, mortality, and risk factors, were evaluated. The incidence rate of bladder cancer was about 1.6-115; cumulative survival rate was 0.95, mortality rate was 0.5-0.84 and its prevalence in the Iranian population was between 4.10% and 12.8%. The risk of developing malignancy in major risk factor groups, including smoking and opium, was 6.2 (2.04-18.7), increases in protein and animal fat consumption were about 5- and 19-times higher than in the general population, respectively. In terms of occupational exposure, bus and heavy truck drivers were 11.3 (1.3-92.05) more at risk than others. Regarding the increasing trend of this disease, changes in lifestyle to reduce risk factors can be effective in decreasing the incidence and mortality rate of this malignancy.
Identifiants
pubmed: 32185152
doi: 10.2147/RRU.S232417
pii: 232417
pmc: PMC7062394
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
91-103Informations de copyright
© 2020 Kalan Farmanfarma et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Arch Iran Med. 2015 Sep;18(9):567-71
pubmed: 26317596
Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):359-63
pubmed: 16236000
Sci Rep. 2018 Jan 18;8(1):1129
pubmed: 29348548
Asian Pac J Cancer Prev. 2016;17(S3):39-42
pubmed: 27165205
BMC Public Health. 2018 Nov 19;18(1):1266
pubmed: 30453968
J Cell Physiol. 2019 Apr;234(4):3197-3206
pubmed: 30471107
Asian Pac J Cancer Prev. 2016;17(S3):269-73
pubmed: 27165237
Asian Pac J Cancer Prev. 2013;14(5):3117-21
pubmed: 23803089
Asian Pac J Cancer Prev. 2015;16(1):133-7
pubmed: 25640340
Urol J. 2011 Winter;8(1):43-7
pubmed: 21404202
J Infect Dis. 2011 Jul 15;204(2):217-23
pubmed: 21673031
Asia Pac J Clin Oncol. 2019 Apr;15(2):e43-e48
pubmed: 30270510
J Res Health Sci. 2014 Summer;14(3):210-3
pubmed: 25209908
East Mediterr Health J. 2015 Aug 27;21(5):319-25
pubmed: 26343120
Transl Androl Urol. 2019 Feb;8(1):5-11
pubmed: 30976562
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1533-1541
pubmed: 29936728
Asian Pac J Cancer Prev. 2015;16(16):7189-93
pubmed: 26514510
Urol J. 2004 Fall;1(4):250-2
pubmed: 17914700
Tohoku J Exp Med. 2016;239(1):9-15
pubmed: 27098227
Int J Occup Med Environ Health. 2013 Apr;26(2):205-13
pubmed: 23690263
Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):145-50
pubmed: 18439094
Asian Pac J Cancer Prev. 2017 Dec 28;18(12):3225-3230
pubmed: 29281876
J Res Med Sci. 2018 Jan 29;23:4
pubmed: 29456561
Asian Pac J Cancer Prev. 2014;15(23):10193-8
pubmed: 25556447
Cancer Epidemiol. 2016 Dec;45:151-156
pubmed: 27821348
BMC Urol. 2019 Mar 5;19(1):16
pubmed: 30836962
Ann Oncol. 2012 Jun;23(6):1586-93
pubmed: 22039083
Asian Pac J Cancer Prev. 2015;16(8):3273-7
pubmed: 25921131
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):681-4
pubmed: 19827894
South Asian J Cancer. 2015 Jul-Sep;4(3):111-4
pubmed: 26942139
Asian Pac J Cancer Prev. 2012;13(6):2955-60
pubmed: 22938489
Med J Islam Repub Iran. 2015 Aug 29;29:254
pubmed: 26793645
Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):327-30
pubmed: 18712985
Int J Cancer. 2017 Nov 15;141(10):1963-1970
pubmed: 28722206
Urol Oncol. 2010 Nov-Dec;28(6):610-6
pubmed: 19110453
Asian Pac J Cancer Prev. 2011;12(9):2353-8
pubmed: 22296383
Asian Pac J Cancer Prev. 2012;13(10):5053-6
pubmed: 23244109
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Eur Urol Focus. 2018 Sep;4(5):725-730
pubmed: 28753772
PLoS One. 2016 May 24;11(5):e0155669
pubmed: 27219458
Int J Occup Environ Med. 2017 Oct;8(4):191-198
pubmed: 28970593
J Educ Health Promot. 2014 Aug 28;3:77
pubmed: 25250343
J Cancer Res Ther. 2018 Apr-Jun;14(3):532-536
pubmed: 29893311
Eur Urol. 2018 Dec;74(6):784-795
pubmed: 30268659
Arab J Urol. 2018 Jan 17;16(2):206-210
pubmed: 29892483
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):549-52
pubmed: 19256736
Subst Use Misuse. 2008;43(3-4):513-20
pubmed: 18365947
Asian Pac J Cancer Prev. 2015;16(4):1409-13
pubmed: 25743807
Asian Pac J Cancer Prev. 2013;14(12):7517-22
pubmed: 24460327
Glob J Health Sci. 2015 Jul 13;8(3):146-55
pubmed: 26493417
Urol J. 2004 Fall;1(4):253-5
pubmed: 17914701
Urol Ann. 2013 Jul;5(3):190-6
pubmed: 24049384
Caspian J Intern Med. 2016 Winter;7(1):25-30
pubmed: 26958329
Arch Iran Med. 2009 Jan;12(1):15-23
pubmed: 19111024
Investig Clin Urol. 2016 Jun;57 Suppl 1:S14-25
pubmed: 27326403
Asian Pac J Cancer Prev. 2010;11(3):601-6
pubmed: 21039023
Nutrients. 2018 Aug 10;10(8):
pubmed: 30103393
Asian Pac J Cancer Prev. 2014;15(3):1459-63
pubmed: 24606483
Urol Ann. 2014 Apr;6(2):135-8
pubmed: 24833825
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 26811194
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1595-600
pubmed: 17684133
Int J Cancer. 2003 Oct 20;107(1):113-8
pubmed: 12925965